In NSCLC, KRAS G12C was nearly mutually exclusive (≤1.2%) with all actionable driver mutations (e.g., ALK rearrangements, EGFR mutations, and ROS1 rearrangements), limiting targeted treatment options.8 This evidence concerns the gene KRAS and non-small cell lung carcinoma.